Search results
Showing 886 to 900 of 1108 results for infections
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)
Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.